Galmed Pharmaceuticals (NASDAQ:GLMD) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.36) by 13.89 percent. This is a 3.13 percent increase over losses of $(0.32) per share from the same period last year.
Avidity Biosciences Or Dyne Therapeutics – Read On Raymond James’ Rating Skew
Raymond James initiated coverage on Avidity Biosciences Inc (NASDAQ:RNA) with a Strong Buy rating and $29 price target (68% upside) and Dyne Therapeutics Inc (NASDAQ:DYN)…
